Skip to main content

Month: March 2023

InvestmentPitch Media Video Discusses Foremost Lithium and its Pending Acquisition of the Pegmatite-Hosting Lac Simard South Property within Sayona Mining’s Abitibi Hub of Lithium Projects in Quebec

VANCOUVER, British Columbia, March 21, 2023 (GLOBE NEWSWIRE) — Foremost Lithium Resource & Technology Ltd. (CSE:FAT) (OTCQB:FRRSF) (FSE:F0R0), a hard-rock exploration company with a focus on lithium, is acquiring a 100% interest on the Lac Simard South property in Quebec, Canada. The Lac Simard South property, consisting of 120 mining claims covering approximately 20,349 acres, or 8,235 hectares, is located approximately 90 km southwest of Sayona Mining’s North American Lithium Mine, a joint venture with Piedmont Lithium, and 80 km southwest of Val d’Or, a logistics hub for mining services. A Media Snippet accompanying this announcement is available by clicking on the image or link below:For more information, please view the InvestmentPitch Media video which is available for viewing on “InvestmentPitch” and on “YouTube”....

Continue reading

Rain Oncology Announces Oral Presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress

NEWARK, Calif., March 21, 2023 (GLOBE NEWSWIRE) — Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced an abstract accepted as a proffered paper presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress in Lugano, Switzerland.Presentation Title: MDM2 inhibitor milademetan: safety profile and management of adverse events (AEs)Presentation Number: 43OPresenter: Chiara Fabbroni, MD, National Cancer Institute, Milan, ItalySession Date and Time: Tuesday, March 21, 2023, 10:50am-12:10pm Central European TimeLocation: Hall AA copy of the presentation materials can be accessed by visiting the “Resources” section...

Continue reading

Correction: Bank of Åland Plc: Managers’ Transactions (Salonius)

  Bank of Åland PlcManagers’ TransactionsMarch 21, 2023, 11.45 EET Correction to the release published by Bank of Åland Plc on 21 March 2023 at 9:45 EET, regarding the managers transaction´of Anne-Maria Salonius had incorrect transaction volume. The correct transaction volume is 894. Corrected release below: Managers’ Transactions__Person subject to the notification requirementName: Anne-Maria SaloniusPosition: Other senior managerIssuer: Ålandsbanken AbpLEI: 7437006WYM821IJ3MN73Notification type: AMENDMENTReference number: 27680/4/4Amendment comment:Incorrect number of shares__Transaction date: 2023-03-17Outside a trading venue Instrument type: SHARE ISIN: FI0009001127 Nature of transaction: SUBSCRIPTION Transaction details (1): Volume: 894 Unit price: 38.8013 EUR Aggregated transactions (1): Volume: 894 Volume weighted average...

Continue reading

Update Announcement in respect of the Results of the Stub Tender Offer

DISRUPTIVE CAPITAL ACQUISITION COMPANY LIMITED (“DCAC or the Company”) in Respect ofDCAC Shareholders (ISIN Code GG00BMB5XZ39) and DCAC Public Warrant Holders (ISIN Code GG00BMB5XY22) relating to Tender for repurchase of up to 5% of the DCAC Ordinary Shares and all accompanying DCAC Public Warrants held by DCAC Ordinary Shareholders on the Record Date (the “Stub Tender Offer”) Update Announcement in respect of the Results of the Stub Tender Offer 21 March 2023 THIS PRESS RELEASE CONTAINS INFORMATION THAT QUALIFIES OR MAY HAVE QUALIFIED AS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EU MARKET ABUSE REGULATION. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A...

Continue reading

Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23

BERKELEY, Calif. and MAINZ, Germany, March 21, 2023 (GLOBE NEWSWIRE) — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced that Bill Caragol, the Company’s CFO, will present and host one-on-one meetings with investors at the Sidoti March Virtual Investor Conference, taking place on March 22-23, 2023. The presentation will begin at 12:15 ET on March 22, 2023 and can be accessed live here:https://sidoti.zoom.us/webinar/register/WN_apzthw9PRlOrUq5PSD5Dcw. Mainz Biomed will also host virtual one-on-ones with investors on Wednesday and Thursday, March 22-23, 2023. To register for the presentation or one-on-ones, visit www.sidoti.com/events. Registration is free and you don’t need to be a Sidoti client. About Sidoti &...

Continue reading

Semiconductor Advance Packaging Market Poised to Reach USD 61.69 billion by 2029, exhibiting a CAGR of 7.65% | Exactitude Consultancy

Advanced packaging has become critical to integrating improved functionality into a wide range of devices, including cellular phones and cars, by enabling high device density in a small footprint. It enables the combination and packaging of several devices such as electrical, mechanical, or semiconductor, into a single electronic device. Advanced packaging, as opposed to traditional electronic packaging, makes use of processes and techniques that are conducted at semiconductor production facilities. Luton, Bedfordshire, United Kingdom, March 21, 2023 (GLOBE NEWSWIRE) — Exactitude Consultancy, the market research and consulting wing of Ameliorate Digital Consultancy Private Limited has completed and published the final copy of the detailed research report on the Semiconductor Advance Packaging Market. The global semiconductor advanced...

Continue reading

ABC arbitrage: Results 2022

 2022 Results: M€29.2 2022 ROE: 18% – 2022 Distributions: €0.41 (83%) The Board of Directors of ABC arbitrage, presided by the Chairman Dominique Ceolin, met on March 16, 2023 to approve the consolidated financial statements for fiscal year 2022.In EUR millions Dec. 31, 2022 IFRS Dec. 31, 2021 IFRS Dec. 31, 2020 IFRSNet revenues €61.2m €64.1m €68.8mNet income €29.2m €28.0m €35.1mEarnings per share (EPS) €0.49 €0.48 €0.60Return On Equity (ROE) 18.0% 17.5% 23.9%Equity €162m €160m €154mContext – 2022 has been a complex year around the world and in the financial markets. The war in Ukraine, very European from an economic point of view, created major international de-correlations across markets, initially leaving the European continent struggling alone. Ultimately,...

Continue reading

SkiStar Half-Year Report September 2022-February 2023

CONTINUED GROWTH AND A VERY STRONG PROFIT FOR THE IMPORTANT SECOND QUARTER Second QuarterNet sales for the second quarter increased by SEK 172 million (8 percent) to SEK 2,350 (2,178) million compared with the same period of the previous year. Profit before tax for the second quarter improved by SEK 6 million (1 percent) to SEK 926 (920) million compared with the same period of the previous year. Earnings per share before and after dilution amounted to SEK 9.32 (9.57).First Six MonthsNet sales for the first six months of the year increased by SEK 195 million (8 percent) to SEK 2,527 (2,333) million compared with the same period of the previous year. Profit before tax for the first six months of the year decreased by SEK 122 million (21 percent) to SEK 451 (573) million compared with the same period of the previous year. Earnings...

Continue reading

Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis

Approximately seven times as many patients aged 6 months to 5 years with severe atopic dermatitis treated with Dupixent experienced clear or almost clear skin and reduced overall disease severity compared to placebo Patients treated with Dupixent achieved rapid itch reduction as early as three weeks after start of therapy, with significant improvements at 16 weeks sustained through one year Dupixent is now a treatment option for the approximately 80,000 infants and young children living with uncontrolled severe atopic dermatitis in Europe Milestone marks third European Commission approval for Dupixent in the past four months TARRYTOWN, N.Y. and PARIS, March 21, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent® (dupilumab) in...

Continue reading

KoinWorks Levels Up Customer Support Using Freshworks Solutions, Resulting in Higher CSAT Scores

Indonesian fintech startup increases its customer satisfaction score by 60% using Freshdesk for better query handling and response time improvements JAKARTA, Indonesia, March 21, 2023 (GLOBE NEWSWIRE) — Freshworks Inc. (NASDAQ: FRSH) announced today that Indonesian financial technology startup, KoinWorks, has increased customer satisfaction after implementing Freshdesk™ to unify its customer support across different channels. KoinWorks, which started as a peer-to-peer financial lending startup in 2016, has grown to become the first credit-led Micro, Small, and Medium Enterprises (MSMEs) neobank with more than 2.5 million users. As the company scaled, the volume of customer queries increased as well – especially between 2021 and 2022, when the customer support team handled close to 28,000 queries across multiple channels....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.